劲方医药正式登陆港交所：开盘上涨超136%，多项发行数据刷新港股18A纪录

Core Viewpoint - The article highlights the successful IPO of Jinfang Pharmaceutical Technology (Shanghai) Co., Ltd., marking it as the first biotech company in the Hong Kong IPO phase to hold both a listed new drug and multiple BD (business development) revenue streams [3][5]. Group 1: IPO Details - Jinfang Pharmaceutical officially listed on the Hong Kong Stock Exchange on September 19, 2025, under the stock code "2595" [3]. - The IPO raised a total of $268 million, setting a record for the Hong Kong 18A biotech sector since 2022 [3]. - The cornerstone investment of $100 million also marked a new high for Hong Kong 18A biotech companies since 2022 [3]. Group 2: Company Overview - Founded in 2017, Jinfang focuses on innovative and effective treatment solutions for oncology, autoimmune, and inflammatory diseases, targeting unverified innovative targets and indications with global intellectual property rights [6]. - The company has established a comprehensive and differentiated RAS product matrix, with eight candidate drugs, five of which are in clinical stages, addressing treatment needs for various advanced solid tumors [6]. Group 3: Key Products - The core product GFH925 (Fluorazepine Tablets) is the first KRAS-targeted drug approved in China for treating KRAS G12C mutation non-small cell lung cancer (NSCLC) [6]. - GFH375 (oral KRAS G12D inhibitor) shows promising treatment potential for advanced solid tumors, with ongoing clinical trials and FDA fast track designation for specific indications [7][8]. Group 4: Strategic Partnerships and Revenue - Jinfang has recorded revenue through external collaborations, including a domestic licensing agreement with Innovent Biologics for GFH925 in 2021 [8]. - The company has also secured overseas licensing agreements for GFH009 and GFH375, indicating a robust business development strategy [8]. Group 5: Investor Support - Notable investors include Dinghui Investment and Huagai Capital, both holding over 5% of the company’s shares prior to the IPO [9][10]. - Investors express confidence in Jinfang's potential for sustainable growth and its ability to create value for shareholders and society [10][12].